Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
OB Pharmaceuticals logo — Changing the paradigm of care for seizure related disorders

OB Pharmaceuticals

Changing the paradigm of care for seizure related disorders

Founded 2012 Canada London, Canada 1 employees

General Information

Company Name OB Pharmaceuticals
Founded Year 2012
Location Canada London, Canada +1
Employees 1
Social

Get notified when OB Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About OB Pharmaceuticals

Formed in 2012 and fully operational in 2014, OB Pharmaceuticals conducts the research and development of new molecules that show promise for the treatment of epilepsy and other seizure related disorders. Epilepsy is a chronic neurological disorder characterized by recurrent and often debilitating seizures. A seizure is an abnormal (excessive) electrical activity of the brain that results in some sort of impairment such as the loss of consciousness and/or involuntary muscle movements. Our Drug Pipeline: OB Pharmaceuticals has developed a new class of therapeutics that act at a unique target in the brain to prevent electrical activity that leads to seizures. Our medications not only stop seizures from occurring in preclinical models of epileptic brains but show promise in preventing seizure development. This activity combined with low or no side effects makes these molecules some of the most promising new preclinical medications currently under development. Executive Summary: OB Pharma is developing novel classes of antiepileptic drugs of higher potency, greater efficacy and less undesirable side effects than the current standard of care. More 120 unique small molecules across two structurally distinct chemical families have been synthesized and screened. These novel compounds establish new intellectual property opportunities for pharmaceutical composition and therapeutic method. Our lead candidates have been screened in both classic and novel proprietary preclinical models of epilepsy and seizures resulting from brain injury, both in vitro and in vivo.

No funding data available for OB Pharmaceuticals yet.

Get notified when OB Pharmaceuticals raises funding

OB Pharmaceuticals Alternatives & Competitors

OB Pharmaceuticals vs
GAOMA Therapeutics
GAOMA Therapeutics France

Bioactive Lipids: the Future for Breakthrough Therapeutics

Seed
5 employees
Biotechnology
OB Pharmaceuticals vs
Alivio Therapeutics
Alivio Therapeutics

Pioneering precision immunomodulation to tackle chronic and acute inflammatory disorders at their so...

Grant
Biotechnology, Health Care
OB Pharmaceuticals vs
CuroNZ
CuroNZ New Zealand

Innovative biotech with CNS clinical drug

3 employees

FAQ About OB Pharmaceuticals

Changing the paradigm of care for seizure related disorders
OB Pharmaceuticals was founded in 2012.
OB Pharmaceuticals is headquartered in London, Canada.
OB Pharmaceuticals has approximately 1 employees.
Top alternatives and competitors to OB Pharmaceuticals include GAOMA Therapeutics, Alivio Therapeutics, CuroNZ, ALGOMEDIX, INC.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OB Pharmaceuticals and GAOMA Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors OB Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy